A large-scale US study suggests that a widely prescribed class of diabetes medications may significantly lower the risk of dementia looming over patients with major depressive disorder, bipolar disorder, or schizophrenia. The research points to a critical metabolic intersection between mental illness and neurodegeneration.
The target trial emulation analyzed Department of Veterans Affairs records for 112,725 older adults from 2016 to 2024. The cohort, with a median age of 74 and overwhelmingly male, had no prior history of dementia. Researchers compared outcomes between those newly prescribed sodium-glucose cotransporter 2 inhibitors and those on other standard therapies.
The intention-to-treat analysis revealed a 39% reduction in the odds of developing all-cause dementia. The protective association was even more pronounced in the per-protocol analysis, where sustained use correlated with a 46% lower risk. The study also observed a trend toward fewer psychiatric emergency visits, though results for psychiatric hospitalizations were less consistent.
Investigators concluded that the cardiometabolic and mitochondrial effects of this drug class support a neuroprotective role. Given the shared physiological vulnerabilities, the findings position SGLT2 inhibitors as a potential transdiagnostic treatment. However, the observational nature and male-skewed demographics necessitate further research before altering clinical practice.